Evaluation of Transarterial Chemoembolization Protocol with Drug-Eluting Beads in Combination with Lipiodol for Hepatocellular Carcinoma: A Single-Center Controlled Study

Table 4

Multivariate analysis of prognostic factors for progression-free survival.

Variables	HR (95% CI)	value
BCLC classs
C	1
B	0.614 (0.440, 0.856)	0.004
A	0.636 (0.449, 0.901)	0.011
AST (μmol/L)	1.001 (0.999, 1.002)	0.324
PLR	1.001 (1.000, 1.003)	0.058
NLR	1.006 (0.986, 1.028)	0.556
Tumor size	1.025 (0.992, 1.058)	0.137
TACE sessions	0.901 (0.848, 0.958)	0.001

Note. HR: hazard ratio; CI: confidence interval; BCLC: barcelona clinical liver cancer; AST: aspartate aminotransferase; PLR: platelet-to-lymphocyte ratio; NLR: neutrophil-to-lymphocyte ratio; TACE: transcatheter arterial chemoembolization.